Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NicVAX Lot Comparability Study
NCT01375933Phase 3Completed
- Sponsor
- Nabi Biopharmaceuticals
- Start
- May 2011
- Primary completion
- Oct 2011
- Modality
- Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of NicVAX in nicotine dependence (2 arms), sponsored by Nabi Biopharmaceuticals. Primary endpoint: Immunogenicity at Week 14. Started May 2011; status: completed.
02
Drugs
NicVAX
03
Conditions
nicotine dependence
Beyond the preview
Go deeper on NCT01375933.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01375933.